Return to homepagePandemic Pact

Novel DNA based COVID-19 vaccine: A phase 1/1b trial for Australia

  • Funded by National Health and Medical Research Council (NHMRC)
  • Total publications:0 publications

Grant number: GA129715

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2022

  • Known Financial Commitments (USD)

    $2,307,667.56

  • Funder

    National Health and Medical Research Council (NHMRC)

  • Principal Investigator

    N/A

  • Research Location

    Australia

  • Lead Research Institution

    University of Sydney

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Phase 1 clinical trial

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase I

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

This phase 1/1b clinical COVID-19 vaccine trial aims to assess the safety and immune responses of a candidate DNA vaccine made by Bionet-Asia.150 healthy volunteers aged 18 to 75 will be invited to participate. This is a partnership with 4 of Australia's most experienced academic vaccine trial sites, who form an Alliance, known as Vax4COVID and Bionet Asia. If successful larger phase 2 trials will follow. This trial is an important contribution to our goal of developing a COVID-19 vaccine.